Answers are grounded in this paper and cite their sources.
Topical calcineurin inhibitors provide a safe and effective alternative to topical corticosteroid use in the treatment of atopic dermatitis. Although the US Food and Drug Administration (FDA) black box warning for topical calcineurin inhibitors remains, studies have not shown an increased risk of malignancy. These warnings have caused a decline in use in favor of topical steroids. A novel PDE4 inhibitor has shown efficacy and safety in studies up to one year. Further long-term safety data is needed.
No takes yet. Share an insight, caveat, or question.
Papier et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: